Co-Diagnostics, Inc. Announces Advancement of Co-Primers™ Technology in Multiplex SNP Genotyping
June 05 2018 - 5:30AM
Business Wire
Proof of concept study successful in
demonstrating potential SNP multiplexing applications
Co-Diagnostics, Inc. (NASDAQ: CODX) (“Co-Diagnostics” or
the “Company”), a molecular diagnostics company with a unique,
proprietary platform for the development of diagnostic tests,
announced today an advancement in the Company’s Co-Primer™ platform
technology in multiplex tests for SNP detection, which allows for
multiple targets to be identified in a single reaction without
costly and time-consuming re-optimization of primers.
SNP detection refers to finding small-scale but
clinically-significant mutations in a given gene using real-time
polymerase chain reaction (PCR) testing. Medical applications of
SNP detection include identifying the presence of cancer cells or
cell-free genetic material in a liquid or tissue biopsy, and to
determine the distinct type of cancer involved. A real-life example
of this includes being able to identify specific mutation(s) in
genes linked to breast cancer in order to determine a patient’s
prognosis, initiate the most effective and affordable treatment and
to determine whether chemotherapy is necessary. SNP detection is
also used in the agricultural industry to identify variations in
crop genomes associated with desired characteristics such as higher
yield, drought and disease resistance and improved seed
viability.
Multiplexing is the ability to identify several different DNA
sequences (or loci) simultaneously in a single PCR test procedure,
as opposed to conducting several individual procedures. As multiple
SNP targets are added to a multiplexed reaction, the individual
primer pair molecules used in standard PCR reactions must be
designed, optimized and verified independently to ensure they do
not cross-react and affect the outcome (i.e. generate a false
positive result). The recently completed study confirms the ability
of CoPrimers to be used in multiplexed SNP reactions without
subsequent re-optimization, allowing researchers or technicians to
utilize any combination of primer sets without concerns of
cross-reactivity.
Co-Diagnostics CEO Dwight Egan commented: “The unique structure
and cooperative relationship between the Co-Primer molecules
enhance PCR by making the reactions more specific, to better
differentiate between similar target genetic sequences. The medical
and diagnostics industries are more aware than ever of the
importance of correctly and accurately identifying the existence
and genetic variant of cancer in patients afflicted by this
life-altering condition. The Company’s development will further
augment our product offerings, where specificity is the key to
unlocking successful multiplexed reactions. Industry experts have
already recognized the advantages of Co-Primers in being able to
“mix-and-match” primers for SNP mutations and we are confident that
the potential applications of our advanced technology represents a
key opportunity for the Company, and for PCR technology as a
whole.”
About Co-Diagnostics, Inc.:
Co-Diagnostics, Inc., a Utah corporation, is a molecular
diagnostics company that has developed and intends to manufacture
and sell reagents used for diagnostic tests that function via the
detection and/or analysis of nucleic acid molecules (DNA or
RNA).
Forward-Looking Statements:
This press release contains forward-looking statements.
Forward-looking statements can be identified by words such as
"believes," "expects," "estimates," "intends," "may," "plans,"
"will" and similar expressions, or the negative of these words.
Such forward-looking statements are based on facts and conditions
as they exist at the time such statements are made and predictions
as to future facts and conditions. Readers of this press
release are cautioned not to place undue reliance on any
forward-looking statements. The Company does not undertake
any obligation to update any forward-looking statement relating to
matters discussed in this press release, except as may be required
by applicable securities laws.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20180605005732/en/
Company Contact:Co-Diagnostics, Inc.Andrew Benson,
801-438-1036Investor
Relationsinvestors@codiagnostics.comorInvestor
Contact:Lytham Partners, LLCJoe Diaz, Robert Blum and Joe
Dorame602-889-9700codx@lythampartners.com
Co Diagnostics (NASDAQ:CODX)
Historical Stock Chart
From Apr 2024 to May 2024
Co Diagnostics (NASDAQ:CODX)
Historical Stock Chart
From May 2023 to May 2024